Organism: Homo sapiens
Gene: 38744_at
Selected probe(set): 202276_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38744_at (202276_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.214075
Number of Samples:3 / 3

Experimental	sirolimus study 6 (light)
	Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:
Control	sirolimus study 6 (heavy)
	Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:

Relative Expression (log2-ratio):1.9963942
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):1.9112339
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):1.8342705
Number of Samples:2 / 3

Experimental	glioma study 16 (BS-149)
	Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):1.7576494
Number of Samples:4 / 4

Experimental	scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d)
	Whole blood samples collected from adult systemic sclerosis patients at day 56 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:---
Control	scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)
	Whole blood samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1.

Relative Expression (log2-ratio):1.7442465
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):-1.6942654
Number of Samples:6 / 20

Experimental	interstitial lung disease study 5 (HP)
	Peripheral blood mononuclear cells (PBMC´s) obtained from patients with hypersensitive pneumonitis (HP).
Control	normal PBMC sample
	Peripheral blood mononuclear cells (PBMC´s) derived from healthy controls. Control subjects had no lung disease or any other significant medical conditions.

Relative Expression (log2-ratio):1.6761265
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-18)
	Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):1.6320591
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-229)
	Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):1.6284742
Number of Samples:3 / 3

Experimental	renal cell carcinoma study 1 (metastasis)
	Tumor tissue from metastases of patients with renal cell carcinoma (RCC).
Control	adjacent kidney tissue
	Histologically normal tissue from an unaffected site (renal tubules) of patients with renal cell carcinoma (RCC) of the clear cell type.